Program
Lamotrigine
Also written as “lamotrigine”, “Lamotrigine Tablets 25 mg” and “Lamictal”.
Its studies are mostly in Epilepsy · Bipolar Disorder · Epilepsy, Tonic-Clonic · Epilepsies, Partial · Schizophrenia, led by 9 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 330 open or running | phase 4since Aug 14, 2002 | Aug 14, 2002 | none ahead |
| Dr. Reddy's Laboratories | 80 open or running | phase 1since May 26, 2010 | May 26, 2010 | none ahead |
| Teva Pharmaceutical Industries | 40 open or running | phase 1since Jan 30, 2009 | Jan 30, 2009 | none ahead |
| IPCA Laboratories | 20 open or running | phase 1since Jun 11, 2012 | Jun 11, 2012 | none ahead |
| Torrent Pharmaceuticals | 20 open or running | phase 1since Jul 13, 2009 | Jul 13, 2009 | none ahead |
| Viatris | 20 open or running | phase 1since Mar 30, 2008 | Mar 30, 2008 | none ahead |
| alembic-pharmaceuticals-ltd | 10 open or running | phase 1since Jan 9, 2018 | Jan 9, 2018 | none ahead |
| Desitin Arzneimittel | 10 open or running | phase 1since Dec 12, 2023 | Dec 12, 2023 | none ahead |
| Pharmtechnology | 10 open or running | phase 1since Mar 29, 2019 | Mar 29, 2019 | none ahead |
Also a collaborator on its studies: biopharma-services-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 33 studies since Aug 14, 2002.
- May 26, 2010Dr. Reddy's Laboratories's first studies: 2 phase 1 studies in HealthyNew to Dr. Reddy's LaboratoriesDr. Reddy's Laboratories · NCT01131975, NCT01131949
- May 12, 2011Phase 1 study in EpilepsyGlaxoSmithKline · NCT01357902 · 24 enrolled · Hong Kong
- Sep 1, 20112 phase 3 studies in EpilepsyGlaxoSmithKline · NCT01431976, NCT01431963
- Jan 17, 20122 phase 1 studies in HealthyDr. Reddy's Laboratories · NCT01513720, NCT01513681
- May 17, 2012Phase 3 study in Bipolar DisorderGlaxoSmithKline · NCT01602510 · 265 enrolled · China
- Jun 11, 2012IPCA Laboratories's first studies: 2 phase 1 studiesNew to IPCA LaboratoriesIPCA Laboratories · NCT01618825, NCT01618799
- Jun 13, 2013Phase 1 study in EpilepsyGlaxoSmithKline · NCT01879423 · 24 enrolled · China
- Jun 25, 20134 phase 1 studies in HealthyDr. Reddy's Laboratories · NCT01888263, NCT01888250, NCT01888757 and 1 more
- Feb 13, 2014Phase 1 study in EpilepsyGlaxoSmithKline · NCT02064465 · 138 enrolled · China
- Mar 27, 2014Phase 4 study in EpilepsyGlaxoSmithKline · NCT02100644 · 33 enrolled · Japan
- Jul 30, 2015Phase 1 study in Bipolar DisorderGlaxoSmithKline · NCT02513654 · 16 enrolled · China
- Jan 9, 2018alembic-pharmaceuticals-ltd's first study: phase 1 study in BioequivalenceNew to alembic-pharmaceuticals-ltdalembic-pharmaceuticals-ltd · NCT05145608 · 22 enrolled · Canada
- Mar 29, 2019Pharmtechnology's first study: phase 1 study in Healthy AdultsNew to PharmtechnologyPharmtechnology · NCT03898011 · 28 enrolled · Russian Federation
- Dec 12, 2023Desitin Arzneimittel's first study: phase 1 study in FastingNew to Desitin ArzneimittelDesitin Arzneimittel · NCT06199791 · 24 enrolled · Canada
TargetBeta
“Sodium channel alpha subunit blocker”ChEMBL 37, by rule
Other programs on the same 10 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Lidocainerule | Keenova Therapeutics | phase 4 | 63 |
| Carbamazepinerule | grin-therapeutics-inc | phase 4 | 21 |
| Dronedaronerule | Sanofi | phase 4 | 18 |
| chloroprocainerule | sintetica-sa | phase 4 | 8 |
| Riluzolerule | Sanofi | phase 4 | 6 |
| Prilocainerule | Haisco Pharmaceutical Group | phase 4 | 2 |
| Carticainerule | Laboratoires Thea | phase 4 | 1 |
| Ropivacainerule | painreform-ltd | phase 3 | 17 |
| Phenytoinrule | Viatris | phase 3 | 10 |
| rufinamiderule | Eisai | phase 3 | 7 |
Studies
All 54 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06199791Fasting · Canada | 1 | Completed | Desitin Arzneimittel | May 9, 2023 | 24 |
| NCT03898011Healthy Adults · Russian Federation | 1 | Completed | Pharmtechnology | May 4, 2019 | 28 |
| NCT05145608Bioequivalence · Canada | 1 | Completed | alembic-pharmaceuticals-ltd | Feb 21, 2018 | 22 |
| NCT02513654Bipolar Disorder · China | 1 | Completed | GlaxoSmithKline | Nov 11, 2015 | 16 |
| NCT02100644Epilepsy · Japan | 4 | Completed | GlaxoSmithKline | May 11, 2015 | 33 |
| NCT02064465Epilepsy · China | 1 | Completed | GlaxoSmithKline | Jul 8, 2014 | 138 |
| NCT01888757Healthy · India | 1 | Completed | Dr. Reddy's Laboratories | Sep 2010 | 62 |
| NCT01888731Healthy · India | 1 | Completed | Dr. Reddy's Laboratories | Aug 2010 | 62 |
| NCT01888263Healthy · India | 1 | Completed | Dr. Reddy's Laboratories | Aug 2010 | 32 |
| NCT01888250Healthy · India | 1 | Completed | Dr. Reddy's Laboratories | Aug 2010 | 36 |
| NCT01879423Epilepsy · China | 1 | Completed | GlaxoSmithKline | Jun 6, 2013 | 24 |
| NCT01618825Lecithin Cholesterol Acyltransferase Deficiency · India | 1 | Completed | IPCA Laboratories | May 2012 | 28 |
| NCT01618799Fasting State · India | 1 | Completed | IPCA Laboratories | May 2012 | 28 |
| NCT01602510Bipolar Disorder · China | 3 | Completed | GlaxoSmithKline | Dec 2015 | 265 |
| NCT01513720Healthy · United States | 1 | Completed | Dr. Reddy's Laboratories | Dec 2002 | 20 |
| NCT01513681Healthy · United States | 1 | Completed | Dr. Reddy's Laboratories | Nov 2002 | 20 |
| NCT01431976Epilepsy · Japan, Korea, Republic of | 3 | Completed | GlaxoSmithKline | Feb 2014 | 20 |
| NCT01431963Epilepsy · Japan, Korea, Republic of | 3 | Completed | GlaxoSmithKline | Mar 2013 | 70 |
| NCT01357902Epilepsy · Hong Kong | 1 | Completed | GlaxoSmithKline | May 23, 2011 | 24 |
| NCT01131975Healthy · United States | 1 | Completed | Dr. Reddy's Laboratories | Feb 2003 | 26 |
| NCT01131949Healthy · United States | 1 | Completed | Dr. Reddy's Laboratories | Feb 2003 | 26 |
| NCT00939614Healthy · India | 1 | Completed | Torrent Pharmaceuticals | ||
| NCT00939458Healthy · India | 1 | Completed | Torrent Pharmaceuticals | ||
| NCT00838279Healthy · Canada | 1 | Completed | Teva Pharmaceutical Industries | Mar 2002 | 32 |
| NCT00838136Healthy · Canada | 1 | Completed | Teva Pharmaceutical Industries | Mar 2002 | 32 |
| NCT00835263Healthy · Canada | 1 | Completed | Teva Pharmaceutical Industries | Feb 2002 | 32 |
| NCT00834561Healthy · Canada | 1 | Completed | Teva Pharmaceutical Industries | Feb 2002 | 32 |
| NCT00723450Bipolar Disorder · United States | 3 | Completed | GlaxoSmithKline | Aug 2013 | 301 |
| NCT00650208Healthy · United States | 1 | Completed | Viatris | Aug 2004 | 27 |
| NCT00647751Healthy · United States | 1 | Completed | Viatris | Aug 2004 | 28 |
| NCT00627575Epilepsy · United States | 1 | Completed | GlaxoSmithKline | Sep 12, 2008 | 119 |
| NCT00605371Epilepsy · United States | 1 | Completed | GlaxoSmithKline | Mar 6, 2008 | 209 |
| NCT00579982Mood Disorders · United States | 3 | Completed | GlaxoSmithKline | Feb 2008 | 97 |
| NCT00566020Bipolar Disorder · Japan | 3 | Completed | GlaxoSmithKline | Oct 2010 | 92 |
| NCT00550407Bipolar Disorder · Japan | 3 | Completed | GlaxoSmithKline | Oct 2009 | 215 |
| NCT00516139Epilepsy · United States | 3 | Completed | GlaxoSmithKline | Jul 2010 | 122 |
| NCT00449774Mental Disorders · United States | 1 | Completed | GlaxoSmithKline | Jun 19, 2007 | 220 |
| NCT00412191Epilepsy · Germany | 1 | Completed | GlaxoSmithKline | Apr 27, 2007 | 180 |
| NCT00395694Epilepsy · Japan | 3 | Completed | GlaxoSmithKline | Mar 1, 2009 | 102 |
| NCT00360126Bipolar Disorder · Australia | 4 | Completed | GlaxoSmithKline | Feb 2007 | 11 |
| NCT00355082Epilepsies, Partial · United States, Argentina, Chile and more | 3 | Completed | GlaxoSmithKline | Nov 2008 | 226 |
| NCT00264615Epilepsy · United States | 3 | Completed | GlaxoSmithKline | Jun 2006 | 45 |
| NCT00224510Bipolar Disorder · Netherlands, Spain | 3 | Completed | GlaxoSmithKline | Sep 2006 | 120 |
| NCT00144872Seizures · United States | 1 | Completed | GlaxoSmithKline | Apr 22, 2006 | 54 |
| NCT00113165Epilepsy · United States, Argentina, Brazil and more | 3 | Completed | GlaxoSmithKline | Jul 2007 | 244 |
| NCT00104416Epilepsy, Tonic-Clonic · United States, Argentina, Brazil and more | 3 | Completed | GlaxoSmithKline | Jul 2008 | 153 |
| NCT00086593Schizophrenia · United States, Canada, United Kingdom | 3 | Completed | GlaxoSmithKline | Jul 2005 | 209 |
| NCT00071747Schizophrenia · United States | 3 | Completed | GlaxoSmithKline | 176 | |
| NCT00067938Bipolar Disorder · United States | 4 | Completed | GlaxoSmithKline | Aug 2004 | 1,200 |
| NCT00056277Bipolar Disorder · United States | 3 | Completed | GlaxoSmithKline | Aug 1, 2005 | 150 |
| NCT00044278Epilepsy · United States, Argentina, Australia and more | 2 | Completed | GlaxoSmithKline | Jun 2006 | 197 |
| NCT00043914Epilepsy | 4 | Completed | GlaxoSmithKline | Jan 29, 2003 | 72 |
| NCT00043901Epilepsy, Tonic-Clonic · United States, Argentina, Chile and more | 4 | Completed | GlaxoSmithKline | Nov 1, 2003 | 141 |
| NCT00043875Epilepsy · United States, Australia, Estonia and more | 2 | Completed | GlaxoSmithKline | Nov 2003 | 177 |
How it is read
Names in the registry
- “Lamotrigine”, 26 entries
- “lamotrigine”, 12 entries
- “Lamotrigine Tablets 25 mg”, 4 entries
- “Lamictal”, 3 entries
- “Lamotrigine 25 mg Chewable Tablets”, 2 entries
Conditions, from the studies’ own filings
- Epilepsy, 17 studies
- Bipolar Disorder, 11 studies
- Epilepsy, Tonic-Clonic, 2 studies
- Epilepsies, Partial, 2 studies
- Schizophrenia, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.